<DOC>
	<DOCNO>NCT01431547</DOCNO>
	<brief_summary>This study dalotuzumab give monotherapy combination ridaforolimus pediatric participant advance solid tumor . This study three part . Part 1 find maximum tolerate dose ( MTD ) collect pharmacokinetic ( PK ) data dalotuzumab alone . Part 2 find MTD collect PK data dalotuzumab combination ridaforolimus . Part 3 expansion cohort recommend Phase 2 dose ( RPTD ) find Part 2 confirm RPTD look potential efficacy combination therapy .</brief_summary>
	<brief_title>Study Dalotuzumab Alone With Ridaforolimus Pediatric Participants With Advanced Solid Tumors ( MK-8669-062 AM1 )</brief_title>
	<detailed_description />
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Participants age 3 17 year Part 1 study age 6 17 year Parts 2 3 study Histologic cytologic diagnosis malignant solid tumor , include tumor central nervous system lymphoma , progress despite standard therapy effective standard therapy know . Measurable nonmeasurable disease Parts 1 2 ; measurable disease Part 3 Parts 2 3 : must able swallow tablet Performance Status : Lansky Play Scale ≥70 child &lt; 10 year age ; Karnofsky score ≥70 child ≥10 &lt; 16 year ; Eastern Cooperative Oncology Group ( ECOG ) Status 02 patient age 16 old Adequate organ function For female reproductive potential , negative pregnancy test must document within 72 hour receive first dose study medication Participants reproductive potential must agree use ( partner use ) adequate contraception throughout study , start Visit 1 30 day last dose study drug Exclusion criterion : Currently receive investigational agent use investigational device Leukemia Previously receive dalotuzumab IGF1R inhibitor Part 1 History allergic reaction attribute compound similar chemical biologic composition dalotuzumab ridaforolimus Persistent acute toxicity previous therapy ≥Grade 2 ( exclude alopecia , neuropathy , hearing loss ) Uncontrolled intercurrent illness despite adequate therapy Pregnant breastfeeding For Parts 2 3 : requirement concurrent treatment medication inducer inhibitor cytochrome P450 ( CYP3A ) Poorly control Type 1 2 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>